Dietary pyruvate targets cytosolic phospholipase A2 to mitigate inflammation and obesity in mice, offering promising therapeutic implications for metabolic disorders.
- Pyruvate was found to inhibit adipogenic differentiation and prevent obesity-related weight gain and inflammation in mice.
- The study identified cPLA2 as a target of pyruvate, emphasizing the importance of their interaction in mitigating obesity and inflammation.
- Pyruvate administration reduced intracellular lipid accumulation, downregulated adipogenic genes, and lowered inflammatory markers in vitro and in vivo.
- The study establishes pyruvate as a promising therapeutic agent for obesity and related metabolic disorders by targeting cPLA2.
- Insights into pyruvate’s molecular mechanisms provide a basis for further research and development of interventions for metabolic diseases.
Source link
Dietary pyruvate, Obesity, Inflammation, Cytosolic phospholipase A2, Mice, Allergy & Clinical Immunology, Nutrition, Metabolism